Amgen (AMGN) FCF Payout Ratio (2011 - 2026)
Amgen (AMGN) recorded quarterly FCF Payout Ratio of 0.92 in Q1 2026, down 31.13% quarter-over-quarter from 1.34 in Q4 2025, and down 29.55% on a YoY basis from 1.31 in Q1 2025.
Amgen (AMGN) FCF Payout Ratio (2011 - 2026) Analysis & Trends
Amgen's FCF Payout Ratio history runs 16 years deep, the most recent figure standing at 0.92 for Q1 2026.
- In Q1 2026, FCF Payout Ratio fell 29.55% year-over-year to 0.92; the TTM figure through Mar 2026 stood at 0.61 (up 34.73% YoY), while the FY2025 annual figure was 0.63, up 36.08% from the prior year.
- FCF Payout Ratio was 0.92 for Q1 2026 at Amgen, down from 1.34 in the prior quarter.
- In the past five years, FCF Payout Ratio ranged from a high of 3.94 in Q4 2023 to a low of 0.27 in Q4 2024.
- Historically, FCF Payout Ratio has averaged 0.98 across 5 years, with a median of 0.55 in 2022.
- The sharpest annual moves came in 2023 and 2024: FCF Payout Ratio soared 775.79% in 2023, then slumped 93.06% in 2024.
- A 5-year view of FCF Payout Ratio shows it stood at 0.45 in 2022, then jumped by 775.79% to 3.94 in 2023, then plunged by 93.06% to 0.27 in 2024, then jumped by 387.49% to 1.34 in 2025, then plunged by 31.13% to 0.92 in 2026.
- The last three FCF Payout Ratio figures came in at 0.92 (Q1 2026), 1.34 (Q4 2025), and 0.3 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -0.41 |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 0.51 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.87 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 0.72 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 0.92 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.43 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 1.12 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.69 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.92 |
| Dec 31, 2025 | 1.34 |
| Sep 30, 2025 | 0.30 |
| Jun 30, 2025 | 0.67 |
| Mar 31, 2025 | 1.31 |
| Dec 31, 2024 | 0.27 |
| Sep 30, 2024 | 0.37 |
| Jun 30, 2024 | 0.54 |
| Mar 31, 2024 | 2.63 |
| Dec 31, 2023 | 3.94 |
| Sep 30, 2023 | 0.45 |
| Jun 30, 2023 | 0.30 |
| Mar 31, 2023 | 1.58 |
| Dec 31, 2022 | 0.45 |
| Sep 30, 2022 | 0.37 |
| Jun 30, 2022 | 0.62 |
| Mar 31, 2022 | 0.55 |
| Dec 31, 2021 | 0.39 |
| Sep 30, 2021 | 0.46 |
| Jun 30, 2021 | 0.58 |